<p>Bone marrow failure syndromes (BMFS) fall into two broad categories, acquired and inherited, each with its distinct aetiopathogenesis and treatment options. Acquired aplastic anemia (AA) is the most common form in adults. In many cases, it develops when the immune system mistakenly attacks the bone marrow’s stem cells, often driven by overactive cytotoxic T cells, elevated levels of pro-inflammatory cytokines, a loss of the normal immune “brakes” provided by regulatory T cells and inflammation driven by Th17 cells. This hostile setting disrupts normal blood cell production, leading to the bone marrow failure. Certain medications, chemicals like benzene, viral infections, or radiation can trigger the condition in people who are already genetically susceptible. Over time, the damaged bone marrow environment, shortening of telomeres, and the growth of abnormal cell clones can make the disease more complicated to treat and sometimes lead to related disorders such as paroxysmal nocturnal hemoglobinuria or myelodysplastic neoplasms. Inherited BMFS, more often seen in children but sometimes in adults, are caused by genetic changes that can affect DNA repair (Fanconi anemia), telomere maintenance (dyskeratosis congenita), or ribosome production (Diamond–Blackfan anemia, Shwachman–Diamond syndrome), among other pathways. Many inherited forms have associated clinical manifestations apart from the marrow failure, such as developmental anomalies or organ dysfunctions. Differentiating between acquired and inherited BMFS is vital, as treatments differ. Immunosuppressants can help many people with acquired AA, while most inherited cases require a stem cell transplant. Detailed bone marrow studies with better genetic testing can help in accurate diagnoses.</p>